Market closed

Bio-Rad Laboratories/$BIO

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Bio-Rad Laboratories

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Ticker

$BIO
Sector
Health Care

Trading on

NYSE

Industry

Life Sciences Tools & Services
Headquarters
Hercules, United States

Employees

8,030
Website
www.bio-rad.com

BIO Metrics

BasicAdvanced
$9.6B
-
-$27.41
0.95
-

$9.6B

0.95

$369.91

$262.12

162K

6.136

4.208

17.949

18.538

6.80%

1.85%

-9.79%

3.768

1.28

1.42

38.075

-5.15%

406.39%

-4.68%

-50.09%

What the Analysts think about BIO

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Bio-Rad Laboratories stock.

BIO Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

BIO Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

BIO News

AllArticlesVideos
Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference

Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference

Business Wire·2 weeks ago
Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference

Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference

Business Wire·2 months ago
Bio-Rad Laboratories, Inc. (BIO) Q3 2024 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (BIO) Q3 2024 Earnings Call Transcript

Seeking Alpha·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BIO

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Bio-Rad Laboratories stock?

Bio-Rad Laboratories (BIO) has a market cap of $9.6B as of January 15, 2025.

What is the P/E ratio for Bio-Rad Laboratories stock?

The price to earnings (P/E) ratio for Bio-Rad Laboratories (BIO) stock is 0 as of January 15, 2025.

Does Bio-Rad Laboratories stock pay dividends?

No, Bio-Rad Laboratories (BIO) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Bio-Rad Laboratories dividend payment date?

Bio-Rad Laboratories (BIO) stock does not pay dividends to its shareholders.

What is the beta indicator for Bio-Rad Laboratories?

Bio-Rad Laboratories (BIO) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.